
Bafna (BAFNAPH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
390.6M
Gross Profit
124.8M
31.94%
Operating Income
29.0M
7.42%
Net Income
13.1M
3.36%
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
682.7M
Shareholders Equity
848.1M
Debt to Equity
0.81
Cash Flow Metrics
Revenue & Profitability Trend
Bafna Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.5B | 1.5B | 1.2B | 851.4M | 712.2M |
Cost of Goods Sold | 1.0B | 1.1B | 765.9M | 512.8M | 454.6M |
Gross Profit | 428.0M | 455.6M | 387.6M | 338.6M | 257.6M |
Gross Margin % | 29.3% | 29.9% | 33.6% | 39.8% | 36.2% |
Operating Expenses | |||||
Research & Development | - | 2.7M | 7.2M | 14.7M | - |
Selling, General & Administrative | - | 85.3M | 20.4M | 25.8M | 7.8M |
Other Operating Expenses | 105.9M | 54.2M | 38.6M | 30.2M | 18.6M |
Total Operating Expenses | 105.9M | 142.1M | 66.3M | 70.6M | 26.4M |
Operating Income | 62.9M | 74.0M | 120.7M | 66.1M | 61.4M |
Operating Margin % | 4.3% | 4.9% | 10.5% | 7.8% | 8.6% |
Non-Operating Items | |||||
Interest Income | - | 1.3M | 445.0K | 336.0K | 395.0K |
Interest Expense | 27.3M | 19.4M | 18.0M | 5.2M | 886.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 41.5M | 73.5M | 116.2M | 52.2M | 58.3M |
Income Tax | 0 | 0 | 2.8M | 0 | 0 |
Effective Tax Rate % | 0.0% | 0.0% | 2.4% | 0.0% | 0.0% |
Net Income | 41.5M | 73.5M | 113.4M | 52.2M | 58.3M |
Net Margin % | 2.8% | 4.8% | 9.8% | 6.1% | 8.2% |
Key Metrics | |||||
EBITDA | 139.2M | 142.9M | 187.0M | 133.6M | 103.9M |
EPS (Basic) | ₹1.76 | ₹3.11 | ₹4.79 | ₹2.21 | ₹2.46 |
EPS (Diluted) | ₹1.76 | ₹3.11 | ₹4.79 | ₹2.21 | ₹2.46 |
Basic Shares Outstanding | 23593750 | 23656000 | 23656000 | 23656000 | 23685772 |
Diluted Shares Outstanding | 23593750 | 23656000 | 23656000 | 23656000 | 23685772 |
Income Statement Trend
Bafna Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 34.3M | 14.0M | 78.1M | 194.0K | 7.5M |
Short-term Investments | - | 7.0M | - | - | - |
Accounts Receivable | 401.7M | 453.9M | 411.5M | 147.8M | 95.6M |
Inventory | 280.9M | 296.4M | 222.2M | 202.8M | 154.4M |
Other Current Assets | 127.1M | 166.1M | 156.0M | 161.7M | -1.0K |
Total Current Assets | 861.8M | 944.7M | 873.1M | 508.8M | 496.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 587.8M | 148.5M | 141.3M | 131.1M | 393.1M |
Goodwill | 0 | 17.7M | 15.0M | 0 | 0 |
Intangible Assets | - | 17.7M | 15.0M | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | -2.0K | -3.0K | -2.0K | -2.0K |
Total Non-Current Assets | 669.0M | 532.1M | 422.7M | 392.6M | 368.0M |
Total Assets | 1.5B | 1.5B | 1.3B | 901.4M | 864.7M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 309.5M | 354.2M | 284.6M | 124.0M | 106.9M |
Short-term Debt | 141.7M | 136.4M | 144.9M | 57.4M | 105.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 26.0M | 18.3M | 21.2M | 21.5M | 21.5M |
Total Current Liabilities | 518.5M | 540.8M | 464.8M | 220.1M | 243.1M |
Non-Current Liabilities | |||||
Long-term Debt | 140.3M | 107.5M | 84.3M | 53.2M | 25.0M |
Deferred Tax Liabilities | - | - | - | 0 | 0 |
Other Non-Current Liabilities | - | 3.0K | - | 10.7M | 1.0K |
Total Non-Current Liabilities | 164.2M | 127.6M | 96.5M | 61.7M | 53.9M |
Total Liabilities | 682.7M | 668.4M | 561.3M | 281.8M | 296.9M |
Equity | |||||
Common Stock | 236.6M | 236.6M | 236.6M | 236.6M | 236.6M |
Retained Earnings | - | -471.0M | -544.8M | -659.7M | -711.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 848.1M | 808.4M | 734.5M | 619.6M | 567.7M |
Key Metrics | |||||
Total Debt | 282.0M | 243.9M | 229.2M | 110.6M | 130.0M |
Working Capital | 343.3M | 403.9M | 408.4M | 288.7M | 253.6M |
Balance Sheet Composition
Bafna Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 41.5M | 73.5M | 116.2M | 51.9M | 58.3M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 120.1M | -126.8M | -297.0M | -145.7M | -214.0M |
Operating Cash Flow | 207.7M | -32.7M | -164.1M | -93.7M | -162.4M |
Investing Activities | |||||
Capital Expenditures | -218.0M | -154.1M | -65.2M | -75.4M | -60.9M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -5.0K | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -213.0M | -149.1M | -60.2M | -65.6M | -53.8M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | - | - | - | -88.2M | 98.7M |
Free Cash Flow | 2.8M | -63.6M | -32.7M | 21.9M | -197.0M |
Net Change in Cash | -5.4M | -181.8M | -224.3M | -247.5M | -117.5M |
Cash Flow Trend
Bafna Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.29
Price to Book
2.78
Price to Sales
1.60
PEG Ratio
-0.05
Profitability Ratios
Profit Margin
5.62%
Operating Margin
10.68%
Return on Equity
4.90%
Return on Assets
2.71%
Financial Health
Current Ratio
1.66
Debt to Equity
33.25
Beta
0.19
Per Share Data
EPS (TTM)
₹3.50
Book Value per Share
₹35.58
Revenue per Share
₹62.14
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
bafnaph | 2.4B | 28.29 | 2.78 | 4.90% | 5.62% | 33.25 |
Sun Pharmaceutical | 3.9T | 37.74 | 5.43 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.87 | 10.91 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 47.8B | -13.92 | -21.95 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 43.0B | 22.81 | 3.14 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 44.3B | 153.95 | 6.28 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.